Trxade Group, Inc. (OTCMKTS:TRXD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Trxade Group, Inc. (OTCMKTS:TRXD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a) Resignation of Gary Augusta as a member of the Board of Directors

Effective on November 20, 2019, Gary Augusta, who was appointed as a member of the Board of Directors of Trxade Group, Inc. (the “Company”, “we” and “us”) on October 9, 2019, resigned as a member of the Board of Directors. Mr. Augusta’s resignation was mutually agreed to by the Company and Mr. Augusta and there were no disagreements between the parties. Mr. Augusta will be actively participating in the Company’s planned Nasdaq Capital Market uplisting process and as such, it was determined that he will likely not fit within the definition of an independent director under applicable Nasdaq Capital Market rules.

Mr. Augusta’s resignation was not in connection with a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Augusta did not serve on any Committees of the Board of Directors prior to his resignation.

(d) Appointment of Dr. Pamela Tenaerts as a member of the Board of Directors

Effective on November 20, 2019, the Board of Directors of the Company appointed Dr. Pamela Tenaerts as a member of the Board of Directors to fill the vacancy created by Mr. Augusta’s resignation, to the power provided to the Board of Directors by the Bylaws of the Company and Delaware law. The Board of Directors also affirmatively determined that Dr. Tenaerts was “independent” under Nasdaq Capital Market rules and guidance.

Dr. Tenaerts is not a party to any material plan, contract or arrangement (whether or not written) with the Company and there are no arrangements or understandings between Dr. Tenaerts and any other person to which she was selected to serve as a director of the Company, nor is she a participant in any related party transaction required to be reported to Item 404(a) of Regulation S-K.

There are no family relationships between any director or executive officer of the Company, including, but not limited to Dr. Tenaerts.

Dr. Tenaerts was appointed to the Audit Committee of the Board of Directors in connection with her appointment to the Board of Directors.

Biographical information for Dr. Tenaerts is provided below:

Dr. Pamela Tenaerts (Age 54)

Since May 2012, Dr. Tenaerts has served as the Executive Director of the Clinical Trials Transformation Initiative (CTTI), located at Duke University, where she works closely with the Executive Committee to develop and implement strategies to accomplish CTTI’s mission. CTTI is a public-private partnership with the goal of developing and driving adoption of practices that will increase the quality and efficiency of clinical trials. She provides senior level oversight of the day-to-day operations of CTTI and orchestrates efforts to effectively engage all interested stakeholders to improve the conduct of clinical trials. Prior to jointing CTTI, Dr. Tenaerts served as Director of European Operations with CoAxia, Inc. (a medical device company focused on cerebral ischemia, “CoAxia”), from April 2007 to May 2012 and as Director Clinical Programs with CoAxia, from April 2007 to April 2011, where she was responsible for leading outside of the U.S. efforts, overall planning, organization, coordination and implementation of clinical research and early market adoption activities in Europe and other locations. Prior to CoAxia, Dr. Tenaerts served as Director of the Clinical Research Center and Center for Advanced Surgery at Sarasota Memorial Hospital from August 1995 to April 2007, where she directed a multi-specialty centralized clinical trials office. Her previous work experience includes serving as the European Coordinator for a 41,000 patient Phase III study of thrombolytic therapy at the University of Leuven, and later as the North American Coordinator for an international Phase II study of anti-thrombin therapy at Duke University Medical Center. She also practiced medicine in both the emergency department and private practice setting for several years before embarking on her career in research.

Dr. Tenaerts is on the Board of Directors for the Society of Clinical Trials and a member of DIA’s Advisory Council North America, MIT’s Collaborative Initiatives Clinical Trials Process Expert Advisory Board, and the DiMe Society’s Scientific Advisory Board.

Dr. Tenaerts received her M.D. from Catholic University of Leuven, Belgium, and an M.B.A. from the University of South Florida. She speaks five languages and has obtained Six Sigma Green Belt certification.

Item 8.01 Other Events.

On November 20, 2019, the Board of Directors of the Company formed a Nominating and Corporate Governance Committee and adopted a charter of the Nominating and Corporate Governance Committee, a copy of which is filed herewith as Exhibit 99.1, and incorporated by reference into this Item 8.01.

On the same date, the Board of Directors appointed Mr. Donald G. Fell (Chairman) and Mr. Michael L. Peterson, as members of the Nominating and Corporate Governance Committee.

As of the date of this filing the membership of the Committees of the Board of Directors of the Company are as follows:

99.1* Charter of the Nominating and Corporate Governance Committee

* Filed herewith.


TRXADE GROUP, INC. Exhibit
EX-99.1 2 ex99-1.htm   TRXADE GROUP,…
To view the full exhibit click here

Story continues below

About Trxade Group, Inc. (OTCMKTS:TRXD)

Trxade Group, Inc. (Trxade) designs, develops, owns and operates a business-to-business Web-based marketplace focused on the United States pharmaceutical industry. The Company’s products and services include Trxade.com, InventoryRx.com, Pharmabayonline and RxGuru. Its services are distributed through its online platform. As of December 31, 2015, its wholesale division distributed pharmaceuticals to independent pharmacies in 26 states through a third-party logistics company. The Company’s subsidiaries include Trxade, Inc. (Trxade Florida) and Pinnacle Tek, Inc. Trxade.com is a Web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and pharmaceutical suppliers across the nation. InventoryRx.com is a Web-based pharmaceutical marketplace formed to promote and enable trade among suppliers, manufacturers and healthcare facilities across the nation.

An ad to help with our costs